Menu Search
Equities

Zealand Pharma A/S

ZEAL:CPH

Zealand Pharma A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)697.00
  • Today's Change-13.50 / -1.90%
  • Shares traded204.63k
  • 1 Year change+119.18%
  • Beta1.0267
Data delayed at least 15 minutes, as of Nov 21 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 20-Nov-24
Select bar for recommendation details.
Recommendations20-Nov-24
Buy5
Outperform5
Hold3
Sell0
Strong Sell0

Share price forecast in DKK

The 12 analysts offering 12 month price targets for Zealand Pharma A/S have a median target of 1,052.50, with a high estimate of 1,100.00 and a low estimate of 815.00. The median estimate represents a 51.00% increase from the last price of 697.00.
High57.8%1,100.00
Med51.0%1,052.50
Low16.9%815.00

Earnings history & estimates in DKK

On Nov 07, 2024, Zealand Pharma A/S reported 3rd quarter 2024 losses of -3.77 per share.
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate+3.09%
Zealand Pharma A/S reported annual 2023 losses of -12.44 per share on Feb 27, 2024.
Average growth rate+1.13%
More ▼

Revenue history & estimates in DKK

Zealand Pharma A/S had 3rd quarter 2024 revenues of 4.42m. This missed the 54.77m consensus estimate of the 6 analysts following the company. This was 67.60% below the prior year's 3rd quarter results.
Average growth rate-22.02%
Zealand Pharma A/S had revenues for the full year 2023 of 342.79m. This was 78.91% above the prior year's results.
Average growth rate+195.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.